The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also accelerating. This longitudinal serolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Benschop, Robert J., Tuttle, Jay L., Zhang, Lin, Poorbaugh, Josh, Kallewaard, Nicole L., Vaillancourt, Peter, Crisp, Melissa, Trinh, Thi Ngoc Vy, Freitas, Joshua J., Beasley, Stephanie, Daniels, Montanea, Haustrup, Natalie, Higgs, Richard E., Nirula, Ajay, Cohen, Myron S., Marovich, Mary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210450/
https://www.ncbi.nlm.nih.gov/pubmed/35679357
http://dx.doi.org/10.1126/scitranslmed.abn3041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210450/
https://www.ncbi.nlm.nih.gov/pubmed/35679357
http://dx.doi.org/10.1126/scitranslmed.abn3041

Ejemplares similares